The combination of new drugs targeting the microenvironment, or the epigenome or metabolic pathways responsible for the persistence of CML LSCs will probably increase the cure rate, by targeting BCR-ABL independent mechanisms of resistance, responsible for TKI failure. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.